1. Identification of Patients with Preeclampsia by Measuring Fluorescence of an Amyloid-Binding Aryl Cyano Amide in Human Urine Samples
- Author
-
Jamie P. Do, Kevin J. Cao, Louise C. Laurent, Sylvia Wei, Jerry Yang, and Mana M. Parast
- Subjects
Amyloid ,medicine.medical_specialty ,Reproductive health and childbirth ,Urine ,Neurodegenerative ,030204 cardiovascular system & hematology ,Cardiovascular ,Gastroenterology ,Fluorescence ,Article ,Analytical Chemistry ,Preeclampsia ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Pre-Eclampsia ,Clinical Research ,Pregnancy ,Placenta ,Internal medicine ,Amide ,Nitriles ,medicine ,2.1 Biological and endogenous factors ,Humans ,Aetiology ,030219 obstetrics & reproductive medicine ,Spectrometry ,Contraception/Reproduction ,Aryl ,Chemical Engineering ,medicine.disease ,Amides ,Brain Disorders ,Good Health and Well Being ,Spectrometry, Fluorescence ,medicine.anatomical_structure ,chemistry ,Hypertension ,Female ,Other Chemical Sciences - Abstract
Preeclampsia (PE) is a hypertensive disorder of pregnancy and one of the leading contributors to both maternal and perinatal morbidity and mortality. Reliable diagnostic parameters unique to the disorder that accurately define and diagnose PE are currently unavailable. Recent studies have revealed that PE is accompanied by the accumulation of amyloidogenic deposits in the placenta and the presence of congophilic amyloid-like protein aggregates in the urine. Here, we evaluate the capability of an amyloid-targeting aryl cyano amide (ARCAM-1) fluorophore to identify PE patients from analysis of urine samples. Our results reveal that this probe can distinguish patients with PE from gestationally healthy patients and patients suffering from non-PE hypertension, highlighting the potential for amyloid-targeting fluorophores to help identify PE patients during pregnancy.
- Published
- 2018